MX2020002898A - Formulaciones topicas de cloroprocaina y metodos para utilizar las mismas. - Google Patents

Formulaciones topicas de cloroprocaina y metodos para utilizar las mismas.

Info

Publication number
MX2020002898A
MX2020002898A MX2020002898A MX2020002898A MX2020002898A MX 2020002898 A MX2020002898 A MX 2020002898A MX 2020002898 A MX2020002898 A MX 2020002898A MX 2020002898 A MX2020002898 A MX 2020002898A MX 2020002898 A MX2020002898 A MX 2020002898A
Authority
MX
Mexico
Prior art keywords
chloroprocaine
formulations
topical formulations
dosages
ophthalmic
Prior art date
Application number
MX2020002898A
Other languages
English (en)
Inventor
Clara Bianchi
Elisabetta Donati
Augusto Mitidieri
Original Assignee
Sintetica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sintetica S A filed Critical Sintetica S A
Publication of MX2020002898A publication Critical patent/MX2020002898A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan dosis y formulaciones tópicas de cloroprocaína, incluidos geles y ungüentos, y métodos de fabricación y uso de las mismas que son eficaces, químicamente estables y fisiológicamente balanceadas para la seguridad y la eficacia. Las dosis y formulaciones son particularmente útiles durante los procedimientos oftálmicos o en respuesta a abrasiones o traumatismos oftálmicos en función de su tolerabilidad y farmacocinética.
MX2020002898A 2017-09-15 2018-09-14 Formulaciones topicas de cloroprocaina y metodos para utilizar las mismas. MX2020002898A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762559220P 2017-09-15 2017-09-15
PCT/IB2018/057073 WO2019053657A1 (en) 2017-09-15 2018-09-14 TOPICAL FORMULATIONS OF CHLOROPROCAINE

Publications (1)

Publication Number Publication Date
MX2020002898A true MX2020002898A (es) 2020-11-06

Family

ID=63713967

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002898A MX2020002898A (es) 2017-09-15 2018-09-14 Formulaciones topicas de cloroprocaina y metodos para utilizar las mismas.

Country Status (23)

Country Link
US (3) US10792271B2 (es)
EP (1) EP3681473A1 (es)
JP (1) JP2020533321A (es)
KR (1) KR20200053476A (es)
CN (1) CN111163756B (es)
AU (1) AU2018332212B2 (es)
BR (1) BR112020003095A2 (es)
CA (1) CA3070336C (es)
CL (1) CL2020000665A1 (es)
CO (1) CO2020002985A2 (es)
CR (1) CR20200133A (es)
CU (1) CU20200019A7 (es)
EA (1) EA202090735A1 (es)
EC (1) ECSP20022313A (es)
IL (1) IL273213A (es)
JO (1) JOP20200010A1 (es)
MA (1) MA50241A (es)
MX (1) MX2020002898A (es)
PE (1) PE20201281A1 (es)
PH (1) PH12020550029A1 (es)
SG (1) SG11202000992RA (es)
WO (1) WO2019053657A1 (es)
ZA (1) ZA202000601B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202139993A (zh) * 2020-03-16 2021-11-01 瑞士商辛鐵堤卡公司 具有經改良之功能性的眼用氯普魯卡因(chloroprocaine)凝膠

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
JP2004123634A (ja) * 2002-10-03 2004-04-22 Lion Corp 眼科用組成物
JP2006513224A (ja) * 2002-12-20 2006-04-20 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ エステル局所麻酔薬の組み合わせ
US20050137177A1 (en) * 2003-12-18 2005-06-23 Shafer Steven L. Ester combination local anesthetic
CA2596194A1 (en) * 2004-11-24 2006-06-01 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
ITMI20051633A1 (it) 2005-09-06 2007-03-07 Sint Sa Nuovo uso di una composizione comprendente cloroprocaina hcl nuova composizione comprendente cloroprocaina hcl e metodo per la sua fabbricazione
CN103405576B (zh) * 2013-08-23 2016-03-30 何学忠 一种治疗由焊接强光辐射引起的眼部疾病的滴眼液

Also Published As

Publication number Publication date
US20240216323A1 (en) 2024-07-04
CA3070336C (en) 2022-08-23
SG11202000992RA (en) 2020-03-30
MA50241A (fr) 2020-07-22
EA202090735A1 (ru) 2020-06-22
PH12020550029A1 (en) 2021-02-08
CL2020000665A1 (es) 2020-09-21
CU20200019A7 (es) 2020-11-30
ECSP20022313A (es) 2020-07-31
BR112020003095A2 (pt) 2020-08-25
CN111163756B (zh) 2022-04-15
CO2020002985A2 (es) 2020-05-29
PE20201281A1 (es) 2020-11-24
JP2020533321A (ja) 2020-11-19
CA3070336A1 (en) 2019-03-21
CN111163756A (zh) 2020-05-15
CR20200133A (es) 2020-05-09
US10792271B2 (en) 2020-10-06
JOP20200010A1 (ar) 2022-10-30
US11969403B2 (en) 2024-04-30
EP3681473A1 (en) 2020-07-22
WO2019053657A1 (en) 2019-03-21
US20200390738A1 (en) 2020-12-17
IL273213A (en) 2020-04-30
ZA202000601B (en) 2021-02-24
AU2018332212B2 (en) 2023-03-16
AU2018332212A1 (en) 2020-02-27
US20190083446A1 (en) 2019-03-21
KR20200053476A (ko) 2020-05-18

Similar Documents

Publication Publication Date Title
EP3684353A4 (en) TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
WO2014186742A3 (en) Anhydrous hydrogel composition
MX2019007587A (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
GB2541835A (en) Multivesicular liposome formulations of tranexamic acid
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
EP3873442A4 (en) MANUAL ADMINISTRATION OF BUTYRATE, BETA-HYDROXYBUTYRATE, CANNABIDIOL AND RELATED COMPOUNDS
IL290339A (en) Preparations for local administration containing cannabidiol, a method for their preparation and their use
IN2013MU03583A (es)
EP4335851A3 (en) Pharmaceutical formulations and methods of use thereof
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
MX2019008544A (es) Nueva formulacion estable para anticuerpos anti-fxia.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
PH12019502874A1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
BR112017015387A2 (pt) composição em gel tópica, método de tratamento de uma infecção da pele, composição em gel oftálmica, e, método de tratamento de uma afecção infecciosa do olho ou pálpebra
WO2014121137A3 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
MX2017013795A (es) Combinaciones terapeuticas de tratamientos antivirales y antiinflamatorios.
PH12020550029A1 (en) Topical formulations of chloroprocaine
WO2018105941A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
MX368943B (es) Formulaciones de tripeptido liofilizado estables en almacenamiento.
WO2015100370A3 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof
WO2014145126A3 (en) Methods of treating dyskinesia and related disorders